Literature DB >> 27481008

Gene Therapy for Lung Cancer.

Humberto Lara-Guerra1, Jack A Roth1.   

Abstract

Gene therapy was originally conceived to treat monogenic diseases. The replacement of a defective gene with a functional gene can theoretically cure the disease. In cancer, multiple genetic defects are present and the molecular profile changes during the course of the disease, making the replacement of all defective genes impossible. To overcome these difficulties, various gene therapy strategies have been adopted, including immune stimulation, transfer of suicide genes, inhibition of driver oncogenes, replacement of tumor-suppressor genes that could mediate apoptosis or anti-angiogenesis, and transfer of genes that enhance conventional treatments such as radiotherapy and chemotherapy. Some of these strategies have been tested successfully in non-small-cell lung cancer patients and the results of laboratory studies and clinical trials are reviewed herein.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27481008      PMCID: PMC5443620          DOI: 10.1615/CritRevOncog.2016016084

Source DB:  PubMed          Journal:  Crit Rev Oncog        ISSN: 0893-9675


  53 in total

1.  The role of natural killer cells in adenovirus-mediated p53 gene therapy.

Authors:  J L Carroll; L L Nielsen; S B Pruett; J M Mathis
Journal:  Mol Cancer Ther       Date:  2001-11       Impact factor: 6.261

Review 2.  Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers.

Authors:  Zhaohui Peng
Journal:  Hum Gene Ther       Date:  2005-09       Impact factor: 5.695

Review 3.  Molecular genetics of lung cancer.

Authors:  Yoshitaka Sekido; Kwun M Fong; John D Minna
Journal:  Annu Rev Med       Date:  2001-12-03       Impact factor: 13.739

4.  Expression of several genes in the human chromosome 3p21.3 homozygous deletion region by an adenovirus vector results in tumor suppressor activities in vitro and in vivo.

Authors:  Lin Ji; Masahiko Nishizaki; Boning Gao; David Burbee; Masashi Kondo; Craig Kamibayashi; Kai Xu; Nancy Yen; E Neely Atkinson; Bingliang Fang; Michael I Lerman; Jack A Roth; John D Minna
Journal:  Cancer Res       Date:  2002-05-01       Impact factor: 12.701

5.  Structure of the apoptotic protease-activating factor 1 bound to ADP.

Authors:  Stefan J Riedl; Wenyu Li; Yang Chao; Robert Schwarzenbacher; Yigong Shi
Journal:  Nature       Date:  2005-04-14       Impact factor: 49.962

6.  Adenoviral-mediated p53 gene transfer to non-small cell lung cancer through endobronchial injection.

Authors:  D Weill; M Mack; J Roth; S Swisher; S Proksch; J Merritt; J Nemunaitis
Journal:  Chest       Date:  2000-10       Impact factor: 9.410

7.  Accumulation of p53 protein correlates with a poor prognosis in human lung cancer.

Authors:  D C Quinlan; A G Davidson; C L Summers; H E Warden; H M Doshi
Journal:  Cancer Res       Date:  1992-09-01       Impact factor: 12.701

8.  Phase I study of adenovirus p53 administered by bronchoalveolar lavage in patients with bronchioloalveolar cell lung carcinoma: ECOG 6597.

Authors:  Vicki Keedy; Wei Wang; Joan Schiller; Sunil Chada; Bonnie Slovis; Keith Coffee; John Worrell; Lyn A Thet; David H Johnson; David P Carbone
Journal:  J Clin Oncol       Date:  2008-09-01       Impact factor: 44.544

9.  Comprehensive genomic characterization of squamous cell lung cancers.

Authors: 
Journal:  Nature       Date:  2012-09-09       Impact factor: 49.962

10.  Prognostic significance of p53 and ras gene abnormalities in lung adenocarcinoma patients with stage I disease after curative resection.

Authors:  T Isobe; K Hiyama; Y Yoshida; Y Fujiwara; M Yamakido
Journal:  Jpn J Cancer Res       Date:  1994-12
View more
  7 in total

1.  Effects of inhalable gene transfection as a novel gene therapy for non-small cell lung cancer and malignant pleural mesothelioma.

Authors:  Misa Ichikawa; Naomi Muramatsu; Wataru Matsunaga; Takahiro Ishikawa; Tomoyuki Okuda; Hirokazu Okamoto; Akinobu Gotoh
Journal:  Sci Rep       Date:  2022-05-23       Impact factor: 4.996

Review 2.  Advanced human-relevant in vitro pulmonary platforms for respiratory therapeutics.

Authors:  Arbel Artzy-Schnirman; Sivan Arber Raviv; Ofri Doppelt Flikshtain; Jeny Shklover; Netanel Korin; Adi Gross; Boaz Mizrahi; Avi Schroeder; Josué Sznitman
Journal:  Adv Drug Deliv Rev       Date:  2021-07-29       Impact factor: 15.470

3.  CIK cell-based delivery of recombinant adenovirus KGHV500 carrying the anti-p21Ras scFv gene enhances the anti-tumor effect and safety in lung cancer.

Authors:  Xin-Rui Lin; Xin-Liang Zhou; Qiang Feng; Xin-Yan Pan; Shu-Ling Song; Hong Fang; Jin Lei; Ju-Lun Yang
Journal:  J Cancer Res Clin Oncol       Date:  2019-02-22       Impact factor: 4.322

4.  Calreticulin (CALR)-induced activation of NF-ĸB signaling pathway boosts lung cancer cell proliferation.

Authors:  Fangfang Gao; Xiaoqian Mu; Huijuan Wu; Lijuan Chen; Jie Liu; Yanqiu Zhao
Journal:  Bioengineered       Date:  2022-03       Impact factor: 3.269

5.  Effect of silencing C-erbB-2 on esophageal carcinoma cell biological behaviors by inhibiting IGF-1 pathway activation.

Authors:  Zhigao Niu; Wenping Zhang; Jialun Shi; Xiangdong Li; Hanlei Wu
Journal:  J Cardiothorac Surg       Date:  2021-07-07       Impact factor: 1.637

6.  Ginkgolic acids induce HepG2 cell death via a combination of apoptosis, autophagy and the mitochondrial pathway.

Authors:  Qian-Ming Qi; Yin-Cun Xue; Jian Lv; Di Sun; Jian-Xin Du; Sheng-Qiang Cai; Yun-He Li; Tian-Cun Gu; Mu-Bing Wang
Journal:  Oncol Lett       Date:  2018-03-05       Impact factor: 2.967

Review 7.  Novel Insights into the Therapeutic Potential of Lung-Targeted Gene Transfer in the Most Common Respiratory Diseases.

Authors:  Malik Bisserier; Xiao-Qing Sun; Shahood Fazal; Irene C Turnbull; Sébastien Bonnet; Lahouaria Hadri
Journal:  Cells       Date:  2022-03-12       Impact factor: 7.666

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.